Live tape
Top 8, mentions 7d7,506META2,263 mentions▲ +0.06GOOGL1,504 mentions▲ +0.02NVDA797 mentions▲ +0.09MUSE665 mentions▲ +0.07MSFT602 mentions▲ +0.05SPY568 mentions▲ +0.05QQQ557 mentions▲ +0.08TSLA550 mentions▲ +0.06

Equity · Healthcare

RCUS

Arcus Biosciences, Inc. · NYSE

$27.38 +1.41% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 13 sessions
$32 $26 30 Jun 17 Jul

The line runs $31 on 30 June through $27.38 on 17 July, on a scale from $26 to $32. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of RCUS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 13 sessions over that window: $31 on 30 June 2026 through $27.38 on 17 July 2026.

Market cap $3.5B
52-week range $9 – $31.01
Avg volume 273.6K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

RCUS insider trades

SEC Form 4 · last 90 days · newest reported trade 21 Aug 2026
Open-market buys 0
Open-market sells 3
Net sold $2.12M
Non-trade filings 1
Date Insider Type Shares Value
21 Aug 2026 Azoy Alexander Chief Accounting Officer Sell 2,827 $85K
10 Jul 2026 Jaen Juan C. President Sell 20,067 $574K
09 Jul 2026 Jaen Juan C. President Sell 48,502 $1.46M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
21 Aug 2026 Azoy Alexander Chief Accounting Officer Option exercise 2,827 $44K

RCUS reported financials

SEC EDGAR XBRL

RCUS reported revenue of $33.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$353.0M.

Figure Reported Period
Revenue $33.0M 31 Dec 2025 fiscal year
Net income −$353.0M 31 Dec 2025 fiscal year
Diluted EPS −$3.29 31 Dec 2025 fiscal year
Total assets $924.0M 30 Jun 2026 at period end
Total equity $464.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

RCUS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.72 $41M
31 Mar 2026 Q1 2026 $-1.02 $17M
31 Dec 2025 FY 2025 $-3.29 $247M
30 Sep 2025 Q3 2025 $-1.27 $26M
30 Jun 2025 Q2 2025 $0.00 $160M
31 Mar 2025 Q1 2025 $-1.14 $28M
31 Dec 2024 FY 2024 $-3.14 $258M
30 Sep 2024 Q3 2024 $-1.00 $48M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RCUS institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a RCUS position for the quarter ended 30 Jun 2026 — a combined $282.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +135.7% shares 3,135,057 $96.7M
Fisher Asset Management Held (±25%) −2.3% shares 2,139,396 $66.0M
Marshall Wace Trimmed −48.3% shares 1,945,088 $60.0M
Baker Bros. Advisors Added +103.3% shares 844,816 $26.0M
Two Sigma Investments Added +103.2% shares 635,404 $19.6M
Man Group Added +70.4% shares 137,763 $4.2M
Millennium Management New position 133,110 $4.1M
D. E. Shaw & Co. Trimmed −62.8% shares 96,417 $3.0M
AQR Capital Management Held (±25%) −2.8% shares 83,861 $2.6M
Balyasny Asset Management New position 22,845 $704K

Source: SEC EDGAR 13F filings

RCUS fails-to-deliver

SEC CNS data

On 31 Aug 2026, 3,990 shares of RCUS failed to deliver (about $117K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 3,990 $117K 0.003%
26 Aug 2026 8,867 $280K 0.007%
24 Aug 2026 4,420 $134K 0.003%

Source: SEC fails-to-deliver (CNS) data